Fundraising Fox
AbCellera
also invests · investor profileVancouver · Founded 2012 · 587 employees on LinkedIn · 3 known investors
Find your way into AbCellera
1,169 people in our graph share verified history with the AbCellera team — schools, employers, funds. One of them is your warm intro.
AbCellera develops antibody-based medicines using a technology platform that integrates biology, computation, and engineering, working with pharmaceutical partners on antibody drug programs including bispecifics and antibody drug conjugates. The company operates in the biotech and drug discovery sector, focusing on first-in-class and best-in-class antibody therapeutics for complex targets such as transmembrane proteins.
Founders & leadership
AbCellera was founded in 2012 by Carl Hansen and Kevin Heyries.
Board
Investors · 3
How we know: Alpha Wave Global's portfolio page · Not right? Tell us
How we know: Daniel Gutenberg's portfolio page · Not right? Tell us
How we know: DCVC (Data Collective)'s portfolio page · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$83.1M disclosed across 4 rounds · 2017–2020
▶$74.5MraisedMay 2020 · 14 investors · BiotechnologyRule 506(b)
- Veronique LecaultDirector, Executive Officer
- Michael HaydenDirector
- Andrew BoothExecutive Officer
- Carl HansenExecutive Officer, Director
- Stimart TrynExecutive Officer
- John HamerDirector
- Offering amount
- $74.5M
- Amount sold
- $74.5M
- First sale
- Mar 2020
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$7.7MraisedAug 2018 · 1 investors · BiotechnologyRule 506(b)
- John HamerDirector
- Veronique LecaultDirector
- Andrew BoothDirector
- Carl HansenExecutive Officer, Director
- Offering amount
- $7.7M
- Amount sold
- $7.7M
- First sale
- Aug 2018
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$50KraisedMar 2018 · 1 investors · BiotechnologyRule 506(b)
- Carl HansenExecutive Officer, Director
- Doug JanzenExecutive Officer, Director
- Andrew BoothDirector
- Offering amount
- $484.5K
- Amount sold
- $50K
- First sale
- Mar 2018
- Incorporated
- Corporation, British Columbia, Canada
- Federal exemptions
- 06b
▶$817.9KraisedApr 2017 · 24 investors · BiotechnologyRule 506(b)
- Doug JanzenExecutive Officer, Director
- Carl HansenExecutive Officer, Director
- Andrew BoothDirector
- Offering amount
- $863.3K
- Amount sold
- $817.9K
- First sale
- Mar 2017
- Incorporated
- Corporation, British Columbia, Canada, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through AbCellera went on to found or lead other companies.
Frequently asked questions
- What does AbCellera do?
- AbCellera develops antibody-based medicines using a technology platform that integrates biology, computation, and engineering, working with pharmaceutical partners on antibody drug programs including bispecifics and antibody drug conjugates. The company operates in the biotech and drug discovery sector, focusing on first-in-class and best-in-class antibody therapeutics for complex targets such as transmembrane proteins.
- Who founded AbCellera?
- AbCellera was founded by Carl Hansen, Kevin Heyries in 2012.
- Who are AbCellera's investors?
- AbCellera's investors include Alpha Wave Global, Daniel Gutenberg, DCVC (Data Collective).
- How much funding has AbCellera raised?
- AbCellera has disclosed $83.1M raised across 4 rounds.
- Where is AbCellera headquartered?
- AbCellera is headquartered in Vancouver.